ArticleMycoses2026
Azole Resistance in Candida parapsilosis From Patients With Burns in Mexico: A Genomic and Phylogenetic Analysis.
Article in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida species are common causes of nosocomial infections. Candida parapsilosis has emerged as an important pathogen. Mortality rates associated with invasive C. parapsilosis infections range from 14.5% to 47%, with azole resistance estimated between 4% and 15%. Resistance mechanisms include mutations in ERG11 that diminish azole binding, upregulation of ergosterol biosynthesis genes due to mutations in regulatory factors like UPC2 and NDT80, and increased efflux pump activity.
methodsThirty clinical strains of the C. parapsilosis complex were isolated from bloodstream cultures, biopsies and catheter tips from hospitalised patients from a major rehabilitation centre in Mexico between June 2011 and August 2016. Minimum inhibitory concentrations for fluconazole, voriconazole, itraconazole, caspofungin, micafungin, anidulafungin and amphotericin B were determined using the broth microdilution method. Whole genome sequencing was conducted using Illumina technology, with subsequent assembly and annotation. Analyses included antifungal resistance variant screening, SNP distance, average nucleotide identity and phylogenetic comparisons with publicly available genomes.
resultsMost strains (96.7%, 29/30) were identified as C. parapsilosis sensu stricto, predominantly isolated from blood. Thirty-three percent of isolates showed phenotypic resistance to fluconazole. The SNP-distance and maximum-likelihood phylogenetic analyses revealed two distinct haplotypes and the genotype 1: ERG11
conclusionsC. parapsilosis sensu stricto was the predominant species isolated, with a notable proportion exhibiting resistance to FLU and VOR. The Y132F variant in the ERG11 gene was present in most sequenced isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.